Pfizer (PFE) stock is holding just above $25 in a tight decision zone. The daily chart remains neutral, while shorter-term timeframes have turned more constructive. The stock closed at $25.03 after Pfizer raised its full-year revenue guidance midpoint, setting up a critical test ahead of Q2 earnings.

Key takeaways

• PFE closed at $25.03, above the 20-day EMA ($24.85) but below the 50-day EMA ($25.10) and 200-day EMA ($25.52).
• The hourly chart displays a bullish EMA stack, with price above all three key moving averages.
• Daily RSI14 reads 52.57 — neutral — while the MACD histogram has turned positive at 0.07.
• Pfizer raised the midpoint of its full-year revenue guidance…